Health Policy

How can Health Technology Assessment reshape funding for social care? Our latest analysis explores strategic approaches to HTA-informed funding and the vital role of support networks in building sustainable, equitable social care systems. Read the full piece to see how these strategies are driving meaningful change. #SyenzaNews #HealthEconomics #HealthcareInnovation #costeffectiveness #innovation

🚀 What’s next for robotic surgery in the OR? A new table-integrated robotic surgery system has received FDA authorization, enabling seamless workflow, enhanced precision, and greater efficiency during minimally invasive procedures. Learn how this milestone could reshape surgical practice. #SyenzaNews #MedTech #medicaldevices #innovation

💊 How are phased tariffs set to transform generic drug supply chains? New policies using gradual tariff adjustments are incentivizing manufacturers to reshore production, boosting domestic output and enhancing resilience in pharmaceuticals. Explore the economic and strategic implications for global drug markets. #SyenzaNews #pharmaceuticals #drugdevelopment #MarketAccess #innovation

How is South Africa advancing access to next-generation treatments for diabetes and obesity? Novo Nordisk, through its partnership with Extensior, has secured authorization to release semaglutide, expanding options for patients across the country. Explore what this approval means for local healthcare delivery and market access. #SyenzaNews #pharmaceuticals #drugdevelopment #MarketAccess #innovation

🚀 How is Portugal pioneering global standards in AI health governance? By developing forward-thinking regulatory frameworks and ethical guidelines, the country is ensuring responsible AI adoption across healthcare systems while fostering innovation and trust. Discover how these efforts are shaping the future of digital health worldwide. #SyenzaNews #AIinHealthcare #digitalhealth #governance #innovation

How is NICE expanding treatment options for HFpEF patients? The UK’s National Institute for Health and Care Excellence has approved finerenone, giving clinicians a new evidence-based therapy to improve outcomes in heart failure with preserved ejection fraction. This milestone broadens the therapeutic landscape and reinforces the value of targeted drug development. Read the full analysis. #SyenzaNews #pharmaceuticals #HealthcareInnovation #innovation #MarketAccess

💊 What does South Africa’s approval of generic semaglutide mean for patients and payers? Following patent expiration, the green light for generic versions promises lower costs and wider access to this key treatment for type 2 diabetes and weight management. Explore how this decision could reshape market access and affordability across emerging economies. #SyenzaNews #pharmaceuticals #drugdevelopment #MarketAccess #costeffectiveness

How is expanding tablet manufacturing capacity reshaping pharma supply resilience? Recent capacity boosts are helping manufacturers meet rising demand while reducing disruption risks across global medication flows. This move strengthens continuity for patients and providers alike. Discover the strategic details behind the expansion. #SyenzaNews #pharmaceuticals #drugdevelopment #innovation #strategicplanning

🧐 Why does the US spend 17.5% of GDP on health yet leave coverage so unequal? Adverse selection and asymmetric information distort markets. The “three-legged stool” of reforms covered millions, but durable cost control remains elusive. Read the full analysis → #HealthEconomics #USHealthcare #PolicySolutions #SyenzaNews

📊 How is Portugal turning hospital data into powerful population health insights? A new data platform is enabling deeper analysis of health trends, outcomes, and resource use across patient populations. Explore how this approach is advancing data-driven decision-making in healthcare. #SyenzaNews #digitalhealth #HealthTech #DigitalTransformation #datascience

Could earlier surveillance after TAVR unlock better outcomes at lower cost? 💡📈 A new analysis finds that proactive early‑post‑TAVR surveillance has the potential to be cost‑effective — and in many modeled scenarios, economically dominant — by improving patient outcomes while reducing downstream costs. The piece highlights key assumptions, sensitivity analyses, and implications for clinicians, payers, and policymakers. Read the full article to understand the evidence and what it means for adopting early surveillance strategies. #SyenzaNews #HealthEconomics #HealthTechnology #costeffectiveness #MarketAccess

Can Portugal's generic drug industry weather the storm of growing global instability? 🌍 This analysis shows how supply‑chain shocks, API dependencies and rising costs are pushing Portuguese manufacturers and policymakers toward onshoring, supplier diversification and greener production to safeguard access and long‑term sustainability. ♻️ Read the full article for practical policy recommendations and industry strategies shaping a more resilient generics sector. #SyenzaNews #pharmaceuticals #HealthEconomics #MarketAccess #healthcarepolicy